These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 25213048)

  • 1. Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial.
    Bleecker ER; Lötvall J; O'Byrne PM; Woodcock A; Busse WW; Kerwin EM; Forth R; Medley HV; Nunn C; Jacques L; Bateman ED
    J Allergy Clin Immunol Pract; 2014; 2(5):553-61. PubMed ID: 25213048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial.
    Lin J; Kang J; Lee SH; Wang C; Zhou X; Crawford J; Jacques L; Stone S
    Respir Med; 2015 Jan; 109(1):44-53. PubMed ID: 25524507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluticasone furoate (FF)/vilanterol (100/25 mcg or 200/25 mcg) or FF (100 mcg) in persistent asthma.
    Bernstein DI; Bateman ED; Woodcock A; Toler WT; Forth R; Jacques L; Nunn C; O'Byrne PM
    J Asthma; 2015; 52(10):1073-83. PubMed ID: 26291137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
    Dransfield MT; Feldman G; Korenblat P; LaForce CF; Locantore N; Pistolesi M; Watkins ML; Crim C; Martinez FJ
    Respir Med; 2014 Aug; 108(8):1171-9. PubMed ID: 24998880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
    Kerwin EM; Scott-Wilson C; Sanford L; Rennard S; Agusti A; Barnes N; Crim C
    Respir Med; 2013 Apr; 107(4):560-9. PubMed ID: 23352226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-daily fluticasone furoate/vilanterol versus twice-daily fluticasone propionate/salmeterol in patients with asthma well controlled on ICS/LABA.
    Bernstein D; Andersen L; Forth R; Jacques L; Yates L
    J Asthma; 2018 Sep; 55(9):984-993. PubMed ID: 28961020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
    Siler TM; Kerwin E; Sousa AR; Donald A; Ali R; Church A
    Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
    Siler TM; Nagai A; Scott-Wilson CA; Midwinter DA; Crim C
    Respir Med; 2017 Feb; 123():8-17. PubMed ID: 28137501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.
    Martinez FJ; Boscia J; Feldman G; Scott-Wilson C; Kilbride S; Fabbri L; Crim C; Calverley PM
    Respir Med; 2013 Apr; 107(4):550-9. PubMed ID: 23332861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of Once-Daily Vilanterol/Fluticasone furoate MDI in persistent asthma: Phase 3 OD-INHALE Study.
    Kumar A; Jain MK; Barge VB; Kumar RS; Gupta N; Yadav H; Pal A; Redkar VE; Mondal A; Rathore RK; Daultani P; Jaiswal A; Mehta RT
    J Asthma; 2024 Oct; 61(10):1181-1189. PubMed ID: 38488853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised, double-blind, placebo-controlled, cross-over single dose study of the bronchodilator duration of action of combination fluticasone furoate/vilanterol inhaler in adult asthma.
    Braithwaite I; Williams M; Power S; Pilcher J; Weatherall M; Baines A; Moynihan J; Kempsford R; Beasley R;
    Respir Med; 2016 Oct; 119():115-121. PubMed ID: 27692131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and optimal dosing interval of the long-acting beta₂ agonist, vilanterol, in persistent asthma: a randomised trial.
    Sterling R; Lim J; Frith L; Snowise NG; Jacques L; Haumann B
    Respir Med; 2012 Aug; 106(8):1110-5. PubMed ID: 22520084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety evaluation of once-daily fluticasone furoate/vilanterol in Asian patients with asthma uncontrolled on a low- to mid-strength inhaled corticosteroid or low-dose inhaled corticosteroid/long-acting beta2-agonist.
    Lin J; Tang H; Chen P; Wang H; Kim MK; Crawford J; Jacques L; Stone S
    Allergy Asthma Proc; 2016 Jul; 37(4):302-10. PubMed ID: 27401316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease.
    Bollmeier SG; Prosser TR
    Ann Pharmacother; 2014 Feb; 48(2):250-7. PubMed ID: 24259654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study.
    Nakamura Y; Hozawa S; Sagara H; Ohbayashi H; Lee LA; Crawford J; Tamaoki J; Nishi T; Fowler A
    Curr Med Res Opin; 2021 Sep; 37(9):1657-1665. PubMed ID: 34162298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing.
    Kempsford RD; Oliver A; Bal J; Tombs L; Quinn D
    Respir Med; 2013 Dec; 107(12):1873-80. PubMed ID: 24200619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma.
    Medley H; Orozco S; Allen A
    Clin Ther; 2012 Aug; 34(8):1683-95. PubMed ID: 22796247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety comparison: Fluticasone furoate and fluticasone propionate, after step down from fluticasone furoate/vilanterol in Japanese patients with well-controlled asthma, a randomized trial.
    Adachi M; Goldfrad C; Jacques L; Nishimura Y
    Respir Med; 2016 Nov; 120():78-86. PubMed ID: 27817819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD.
    Agustí A; de Teresa L; De Backer W; Zvarich MT; Locantore N; Barnes N; Bourbeau J; Crim C
    Eur Respir J; 2014 Mar; 43(3):763-72. PubMed ID: 24114969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.